End-Stage Renal Disease
Conditions
Interventions
The traditional priming group:Traditional priming method:Following standard guidelines, the HA130 cartridge and Fx10 filter were primed separately.
The procedure was as follows:
1.Cartridge priming:
the cartridge underwent a dynamic heparinization process involving a 100 mL/min slow flush with 2500 mL of heparinized saline (containing 6,250 U of heparin), followed by a 50 mL/min slow flush with 5
2.Filter priming:the cartridge side was clamped
the filter was primed according to the TSHNA 0006-2023 standard, which involved flushing the blood compartment with 800 mL of normal saline to remove air
3.Final circuit reparation:the dialysate lines were connected to rinse the dialysate compartment and remove external air, followed by a 10-minute closed-loop recirculation with 200 mL of normal saline
The modified priming group:The Second modified priming as follows:
1. The slow-prime phase (a fixed volume of 500 mL of heparinized saline) was delivered at the designated variable flow rate 100 mL/m
2. The fast-flush phase (the designated variable volume of 2000 mL of saline) was delivered at the fixed flow rate of 250 mL/min
3. Rinsing of the dialysate compartment, followed by a final 10-minute closed-loop recirculation with 200 mL of normal saline to complete the process.
Sponsors
The Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) age 18–80 years; (2) receiving stable HAHD therapy (once every two weeks) for at least 3 months; (3) adequate vascular access function with a blood flow >=200 mL/min.
Exclusion criteria
Exclusion criteria: (1) known hypersensitivity or intolerance to dialyzer or hemoadsorption cartridge materials; (2) acute severe infections (defined as uncontrolled systemic sepsis, bacteremia, or active infections causing hemodynamic instability); (3) severe comorbidities (e.g., cardiopulmonary insufficiency, cerebrovascular disease, malignant tumors); (4) high bleeding risk (e.g., bleeding tendency, active bleeding, or platelet count < 50×10^9/L).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood coagulation during cardiopulmonary bypass;Purity of Priming fluid; | — |
Secondary
| Measure | Time frame |
|---|---|
| Solute Clearance Efficacy;Priming Time;Saline volume of Priming;Heparin volume of Priming; | — |
Countries
China
Contacts
Public ContactJing Chen/Bin Dai
The Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital)
Outcome results
None listed